In the last year, we have streamlined the company's novel discovery platform on the generation of compounds for arthritis, asthma, diabetes and other diseases where inflammatory pathways play a critical role, such as cancer, said Lloyd Kunimoto, chief executive officer of Galileo Pharmaceuticals, Inc.